In vitro activity of TNP-2092 against periprosthetic joint infection-associated staphylococci.

Staphylococci are the most common causes of periprosthetic joint infection (PJI). TNP-2092 is an investigational hybrid drug composed of rifamycin and quinolizinone pharmacophores conjugated via a covalent linker. We determined minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and minimum biofilm bactericidal concentration (MBBC) values of TNP-2092 against 80 PJI-associated Staphylococcus aureus and Staphylococcus epidermidis isolates compared to ciprofloxacin and rifampin alone and in combination, alongside daptomycin and vancomycin. TNP-2092 exhibited the following activity against S. aureus: MIC/MIC ≤0.0075/0.015 μg/mL; MBC/MBC, 0.5/4 μg/mL; and MBBC/MBBC, 0.5/2 μg/mL, and the following activity against S. epidermidis: MIC/MIC, ≤0.0075/0.015 μg/mL; MBC/MBC, 0.015/0.125 μg/mL; and MBBC/MBBC, 0.06/0.25 μg/mL. TNP-2092 MIC, MBC, and MBBC values were >8 μg/mL for 1 isolate, while MIC values were ≤0.25 μg/mL and MBC and MBBC values were ≤4 μg/mL for all other isolates. Results of this study show that TNP-2092 has promising in vitro activity against PJI-associated staphylococci.